Non-Systemic Drugs: A Critical Review
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Non-systemic drugs act within the intestinal lumen without reaching the systemic circulation. The first generation included polymeric resins that sequester phosphate ions, potassium ions, or bile acids for the treatment of electrolyte imbalances or hypercholesteremia. The field has evolved towards non-absorbable small molecules or peptides targeting luminal enzymes or transporters for the treatment of mineral metabolism disorders, diabetes, gastrointestinal (GI) disorders, and enteric infections. From a drug design and development perspective, non-systemic agents offer novel opportunities to address unmet medical needs while minimizing toxicity risks, but also present new challenges, including developing a better understanding and control of non-transcellular leakage pathways into the systemic circulation. The pharmacokinetic-pharmacodynamic relationship of drugs acting in the GI tract can be complex due to the variability of intestinal transit, interaction with chyme, and the complex environment of the surface epithelia. We review the main classes of nonabsorbable agents at various stages of development, and their therapeutic potential and limitations. The rapid progress in the identification of intestinal receptors and transporters, their functional characterization and role in metabolic and inflammatory disorders, will undoubtedly renew interest in the development of novel, safe, non-systemic therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Microbial translocation is a cause of systemic immune activation in chronic HIV infection
Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006) · Nature Medicine · doi:10.1038/nm1511 · Cited by 3,559
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027 · cited 12×
“Because of its toxicity, aluminum was later replaced by calcium (acetate and carbonate salts), now generic drugs used in phosphate management for CKD.”
BackgroundResultInfluentialLong term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Identification of an Intestinal Heme Transporter
Shayeghi, M., Latunde-Dada, G. O., Oakhill, J. S., Laftah, A. H., Takeuchi, K., Halliday, N., Khan, Y., Warley, A., McCann, F. E., Hider, R. C., et al. (2005) · Cell · doi:10.1016/j.cell.2005.06.025 · Cited by 755 · cited 2×
“One challenge encountered by this approach is the multiple pathways utilized by the intestinal mucosa to extract dietary iron, one of which is the selective transport of heme-iron [45].”
BackgroundThe importance of the gastrointestinal system in the pathogenesis of heart failure
Krack, A., Sharma, R., Figulla, H. R., & Anker, S. D. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi389 · Cited by 280
Nanoparticle uptake by the oral route: Fulfilling its potential?
Florence, A. T. (2005) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2005.05.019 · Cited by 248
Johnston, J. M., Kurtz, C. B., MacDougall, J. E., Lavins, B. J., Currie, M. G., Fitch, D. A., O'Dea, C., Baird, M., & Lembo, A. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.041 · Cited by 229
Rhee, N. A., Vilsbøll, T., & Knop, F. K. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01505.x · Cited by 47
Cited by
Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform
Kozuka, K., He, Y., Koo-McCoy, S., Kumaraswamy, P., Nie, B., Shaw, K., Chan, P., Leadbetter, M., He, L., Lewis, J. G., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.013 · Cited by 179
“Minimally systemic drugs that target andmodulate these intestinal epithelial functions exert their pharmacological activity with little or no systemic absorption, therebyminimizing unnecessary exposure of other organ systems to the drug and reducing the potential for side effects (Charmot, 2012).”
BackgroundSelf-citationIntestinal phospholipid and lysophospholipid metabolism in cardiometabolic disease
Hui, D. Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000334 · Cited by 67
Gut hormones and gut microbiota: implications for kidney function and hypertension
Afsar, B., Vaziri, N. D., Aslan, G., Tarim, K., & Kanbay, M. (2016) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2016.10.007 · Cited by 63
Metadata
- Authors
- Charmot, D.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2012-04-01
- Volume
- 18
- Issue
- 10
- Pages
- 1434-1445
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2121911364
- Cited by
- 80
- References
- 10
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non-Systemic Drugs: A Critical Review. https://app.cochat.ai/papers/10.2174/138161212799504858
- The paper
- Charmot, D. (2012). Non-Systemic Drugs: A Critical Review. Current Pharmaceutical Design. https://doi.org/10.2174/138161212799504858
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.